Add Company
Join Now

XenoPort Revenue and Competitors

License our Company Data API

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • XenoPort's estimated annual revenue is currently $27.7M per year.(i)
  • XenoPort's estimated revenue per employee is $201,000

Employee Data

  • XenoPort has 138 Employees.(i)
  • XenoPort grew their employee count by 1% last year.

XenoPort's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$53.7M26716%N/AN/A
#2
$53.1M26421%N/AN/A
#3
$69.1M34426%N/AN/A
#4
$22.1M110-10%N/AN/A
#5
$151.8M75511%N/AN/A
#6
$63.9M31813%N/AN/A
#7
$29.9M14913%N/AN/A
#8
$1.7M17-6%$114.3MN/A
#9
$6.8M34-6%N/AN/A
#10
$12.5M62-9%N/AN/A
Add Company

What Is XenoPort?

XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Horizant® (gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in the United States by XenoPort. Regnite® (gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in Japan by Astellas Pharma Inc. XenoPort holds all other world-wide rights to gabapentin enacarbil. XenoPort's pipeline of product candidates includes potential treatments for patients with Parkinson's disease, relapsing-remitting multiple sclerosis and psoriasis.

keywords:N/A

N/A

Total Funding

138

Number of Employees

$27.7M

Revenue (est)

1%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$28.3M13834%N/A
#2
$42.1M1385%N/A
#3
$40M13816%N/A
#4
$22.5M13810%N/A
#5
$37.3M13842%N/A